Given the high burden of cancer in the senior population, and given the increasingly high cost of cancer care, there is a growing interest in value-based oncology care payment models, particularly within CMS.
Given the high burden of cancer in the senior population, and given the increasingly high cost of cancer care, there is a growing interest in value-based oncology care payment models, particularly within CMS.
A recent review, authored by The Center for Biosimilars® advisory board member Kashyap Patel, MD, and colleagues, provides an overview of value-based care models and discusses the role of biosimilars in meeting these models’ objectives.
The review, appearing in Cancer Management and Research, notes that US spending on cancer care grew from $27 billion in 1990 to $124 billion in 2010, with spending levels expected to reach $157 billion in 2020. Globally, spending on oncology and supportive care reached $100 billion in 2014. Among the fastest-growing drug classes in oncology are monoclonal antibodies—many of which are targeted by biosimilar developers—which account for 35% of US oncology spending.
To help address skyrocketing costs, CMS has developed value-based care programs that reward providers with incentives for improving the quality of care they provide to Medicare beneficiaries. These programs seek to move away from the fee-for-service (FFS) model that incentivizes high-quantity (though not necessarily high-quality) care.
In 2016, CMS implemented the Quality Payment Program, which offers payment to providers either through the Merit-based Incentive Payment System or through Advanced Alternative Payment Models, one of which is the Oncology Care Model (OCM).
The OCM is a voluntary program that seeks to provide higher-quality care at the same or lower cost to Medicare than traditional FFS payments. The OCM links payments to provider performance based on meeting quality metrics and making practice reforms.
Biosimilar therapies offer increased affordability and access—as well as improved outcomes and improved health-related quality of life—to patients treated in the OCM model; using lower-cost biosimilar granulocyte-colony stimulating factor therapies, for example, can reduce the incidence of neutropenia, allowing for increased dose administration of patients’ primary treatments and improved survival.
Not only may biosimilars, themselves, be offered at more affordable prices than biologics—as has been demonstrated in experience with biosimilar filgrastim—but they also may drive down overall prices in a given class as a result of market competition, producing substantial US cost savings. These savings, which have the potential to grow with upcoming availability of biosimilar epoetin alfa and biosimilars of targeted therapies, could help physicians to meet the OCM objective of improving patient care while reducing costs.
However, write Patel and colleagues, “Realization of cost savings possible from biosimilars…will require that biosimilars are utilized.” Current gaps in physician education on biosimilars have limited use of these agents, making the need for provider education all the more pressing.
Reference
Patel KB, Arantes LH, Tang WY, Fung S. The role of biosimilars in value-based oncology care. Cancer Manag Res. 2018;10:4591-4602. doi: 10.2147/CMAR.S164201.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.